publication date: Nov. 8, 2019
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.
Lomustine, a.k.a. CCNU, is an old cancer drug.
A couple of years ago, it was hard to obtain but cheap. It has since turned a corner, becoming plentiful but wildly expensive.
David H. Thompson, a professor at the Department of Chemistry at Purdue University and a member of the Purdue Center for Cancer Research, is working on a better and faster way to produce drugs and eliminate shortages.
Texans have approved an additional $3 billion in state funds for the Cancer Prevention and Research Institute of Texas, extending the institute’s operations well past its sunset date in 2023.
Norman E. Sharpless has returned to his previous role of NCI director earlier this week after serving as acting FDA commissioner since April 5.
The Office of Hematology and Oncology Products at FDA has been renamed the Office of Oncologic Diseases—a move that includes an internal reorganization of divisions, as part of modernization plans approved in September 2019.
- Carolyn Hayes named nursing leader at Rutgers Cancer Institute and RWJBarnabas Health
- Elaine Fuchs receives Ohio State’s Block Memorial Lectureship Award
- ACCC recognizes seven cancers programs with Innovator Awards at 36th National Oncology Conference
- Brawley receives University of Chicago Professional Achievement Award
- ASCO, IASLC work to improve lung cancer care in Brazil
- NIH REACH awards five new Hubs $4M each
Each year, the American Society of Clinical Oncology conducts its National Cancer Opinion Survey to better understand Americans’ views on a wide range of cancer-related issues and uncover areas that need to be addressed.
- Phase III trial of Ninlaro as first-line maintenance therapy meets PFS in multiple myeloma
- Inovio demonstrates 80% 6-month PFS in phase II glioblastoma multiforme study with INO-5401 + Libtayo
- AppliedVR and NCI evaluate virtual reality to address cancer-related anxiety
- Thermo Fisher Scientific introduces NGS platform that delivers faster results
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.